Obesity and Diabetes
According to CDC statistics from 2010, 36% of US adults suffer from obesity, 8% suffer from diabetes, 35% suffer from pre-diabetes, and 10-20% suffer from obesity-related fatty liver disease.
Several classes of anti-obesity and anti-diabetic medicines are currently available, but multiple agents are frequently required for adequate treatment, and existing agents are often limited by adverse side effects. More therapeutic options are clearly needed. A therapeutic for fatty liver disease does not exist.
To address these problems, Emmyon is discovering and developing new nutritional and pharmaceutical products for obesity, diabetes and fatty liver disease.